Letters Cancer drugs, survival, and ethics

The Association of Cancer Physicians responds to “Cancer drugs, survival, and ethics”

BMJ 2016; 355 doi: https://doi.org/10.1136/bmj.i6487 (Published 05 December 2016) Cite this as: BMJ 2016;355:i6487
  1. Adam Dangoor, consultant medical oncologist1,
  2. Johnathan Joffe, consultant medical oncologist2,
  3. Adam Januszewski, medical oncology specialist trainee3,
  4. Janine Mansi, consultant medical oncologist4,
  5. David Cunningham, consultant medical oncologist5,
  6. Peter Selby, consultant medical oncologist6
  7. On behalf of 17 other authors and members of the Association of Cancer Physicians, UK
  1. 1Bristol Cancer Institute, Bristol Haematology and Oncology Centre, Bristol BS2 8ED, UK
  2. 2Huddersfield Royal Infirmary, Huddersfield, UK
  3. 3Imperial College, London, UK
  4. 4Guy’s and St Thomas’ Hospital, London, UK
  5. 5Royal Marsden Hospital, London, UK
  6. 6St James’s University Hospital, Leeds, UK
  1. adamd{at}doctors.org.uk

As UK health professionals specialising in the drug treatment of cancer, we think that Wise’s analysis strays into the territory of unbalanced opinion.1 We welcome discussion of topics that we debate ourselves; his article is a useful counterpoint to the hyperbole we often see in the media around incremental improvements in treatment. But he conflates problems from different …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe